Haplotype phasing of CYP2D6: an allelic ratio method using Agena MassARRAY data.

ABSTRACT: Pharmacogenomics aims to use the genetic information of an individual to personalize drug prescribing. There is evidence that pharmacogenomic testing before prescription may prevent adverse drug reactions, increase efficacy, and reduce cost of treatment. CYP2D6 is a key pharmacogene of relevance to multiple therapeutic areas. Indeed, there are prescribing guidelines available for medications based on CYP2D6 enzyme activity as deduced from CYP2D6 genetic data. The Agena MassARRAY system is a cost-effective method of detecting genetic variation that has been clinically applied to other genes. However, its clinical application to CYP2D6 has to date been limited by weaknesses such as the inability to determine which haplotype was present in more than one copy for individuals with more than two

SUBMITTER: Thamilselvan M 

PROVIDER: S-EPMC10861455 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature